Covered recipient · General Payments record
ATULYA A DEODHAR
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$75,637.02
53 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $59,995.20 | 12 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,000.00 | 3 |
| Travel and Lodging | $3,812.04 | 15 |
| Food and Beverage | $1,829.78 | 23 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $40,590.46 | 27 |
| Novartis Pharmaceuticals Corporation | $11,948.96 | 11 |
| Eli Lilly and Company | $11,515.60 | 7 |
| UCB SA | $5,097.60 | 2 |
| E.R. Squibb & Sons, L.L.C. | $4,550.00 | 1 |
| Cipla USA Inc. | $1,500.00 | 1 |
| Aurinia Pharma U.S., Inc. | $187.17 | 1 |
| GENZYME CORPORATION | $120.53 | 1 |
| PFIZER INC. | $96.75 | 1 |
| Janssen Biotech, Inc. | $29.95 | 1 |
Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ATULYA A DEODHAR
NPI 1558376053 · CMS profile ID 24910
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
PORTLAND, OR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ATULYA A DEODHAR, NPI 1558376053, CMS profile ID 24910. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ATULYA A DEODHAR, NPI 1558376053, CMS profile ID 24910. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ATULYA A DEODHAR, NPI 1558376053, CMS profile ID 24910, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–53 of 53 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558376053?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
53 matching records · $75,637.02 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–53 of 53.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $120.53 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139568601 | CMS |
| Novartis Pharmaceuticals Corporation | $9.74 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086916919 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,550.00 | 01/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101316310 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $7,228.33 | 1 |
| PY2025 | Principal investigator | $257,699.41 | 36 |
| PY2024 | Recipient | $5,907.18 | 3 |
| PY2024 | Principal investigator | $344,277.14 | 11 |
| PY2023 | Recipient | $39,848.44 | 13 |
| PY2023 | Principal investigator | $648,728.30 | 14 |
| PY2022 | Recipient | $48,484.00 | 16 |
| PY2022 | Principal investigator | $257,694.66 | 14 |
| PY2021 | Recipient | $30,120.85 | 20 |
| PY2021 | Principal investigator | $251,859.58 | 24 |
| PY2020 | Recipient | $60,189.81 | 46 |
| PY2020 | Principal investigator | $387,756.92 | 21 |
| PY2019 | Recipient | $14,984.68 | 10 |
| PY2019 | Principal investigator | $457,357.00 | 24 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
37 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $2,200.00 | 11/06/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175434766 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $731.19 | 10/27/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract | No dispute reported | 06/30/2026 | 1190297429 |
| Recipient | Novartis Pharmaceuticals Corporation | $7,228.33 | 10/16/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190293785 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,515.66 | 10/01/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCES UNIVERSITY | A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut | No dispute reported | 06/30/2026 | 1190312599 |
| Principal investigator 1 | UCB SA | $2,582.00 | 09/26/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246657940 |
| Principal investigator 1 | UCB SA | $2,582.00 | 09/26/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246657942 |
| Principal investigator 1 | UCB SA | $1,719.00 | 09/26/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246657944 |
| Principal investigator 1 | UCB SA | $500.00 | 09/24/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246656722 |
| Principal investigator 1 | UCB SA | $276.00 | 09/24/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246656724 |
| Principal investigator 1 | UCB SA | $276.00 | 09/24/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246656727 |
| Principal investigator 1 | UCB SA | $276.00 | 09/24/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246656731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,328.00 | 09/08/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175435120 |
| Principal investigator 1 | UCB SA | $5,883.80 | 08/28/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658688 |
| Principal investigator 1 | UCB SA | $276.00 | 06/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658600 |
| Principal investigator 1 | UCB SA | $2,252.00 | 06/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658602 |
| Principal investigator 1 | UCB SA | $276.00 | 06/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658612 |
| Principal investigator 1 | UCB SA | $276.00 | 06/16/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,108.50 | 05/22/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175435267 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $47,040.00 | 05/22/2025 | Non-covered Recipient Entity OHSU APHERESIS COLLECTION UNIT | A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) | No dispute reported | 06/30/2026 | 1190299289 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,145.70 | 05/01/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) | No dispute reported | 06/30/2026 | 1190296673 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $46,330.00 | 04/24/2025 | Non-covered Recipient Entity OHSU APHERESIS COLLECTION UNIT | A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut | No dispute reported | 06/30/2026 | 1190299298 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,377.53 | 04/23/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract | No dispute reported | 06/30/2026 | 1190296677 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $55,040.00 | 03/11/2025 | Non-covered Recipient Entity OHSU APHERESIS COLLECTION UNIT | A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract | No dispute reported | 06/30/2026 | 1190299292 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,570.33 | 01/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1236000440 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $431.42 | 01/21/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) | No dispute reported | 06/30/2026 | 1190297425 |
| Principal investigator 1 | UCB SA | $1,461.00 | 01/20/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658272 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,744.00 | 01/17/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease | No dispute reported | 06/30/2026 | 1175435069 |
| Principal investigator 1 | UCB SA | $276.00 | 01/09/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658318 |
| Principal investigator 1 | UCB SA | $20,506.40 | 01/09/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658320 |
| Principal investigator 1 | UCB SA | $276.00 | 01/09/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658322 |
| Principal investigator 1 | UCB SA | $276.00 | 01/09/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658324 |
| Principal investigator 1 | UCB SA | $276.00 | 01/09/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658326 |
| Principal investigator 1 | UCB SA | $766.60 | 01/09/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS | No dispute reported | 06/30/2026 | 1246658328 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,947.00 | 01/07/2025 | Non-covered Recipient Entity OHSU APHERESIS COLLECTION UNIT | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment | No dispute reported | 06/30/2026 | 1190299218 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,305.25 | 01/01/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) | No dispute reported | 06/30/2026 | 1190295581 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,001.20 | 01/01/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refract | No dispute reported | 06/30/2026 | 1190295585 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $870.83 | 01/01/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut | No dispute reported | 06/30/2026 | 1190295590 |